Evidence map›Paper›PMID 36459980›Full record

ArticleAmerican journal of human genetics2022

Functional characterization of 5p15.33 risk locus in uveal melanoma reveals rs452384 as a functional variant and NKX2.4 as an allele-specific interactor.

Anne-Céline Derrien, Alexandre Houy, Olivier Ganier, Florent Dingli, Massih Ningarhari, Lenha Mobuchon, María Isabel Espejo Díaz, Damarys Loew, Nathalie Cassoux, Olivier Cussenot and 6 more

Open access · hybridAbstract read
In one paragraph

Article in American journal of human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Anne-Céline DerrienInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France.
Alexandre HouyInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France.
Olivier GanierInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France.
Florent DingliInstitut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, 26 rue d'Ulm, Paris 75248 Cedex 05, France.
Massih NingarhariCentre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, 75006 Paris, France; Functional Genomics of Solid Tumors laboratory, Équipe labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, 75006 Paris, France.
Lenha MobuchonInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France.
María Isabel Espejo DíazInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France.
Damarys LoewInstitut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, 26 rue d'Ulm, Paris 75248 Cedex 05, France.
Nathalie CassouxDepartment of Ocular Oncology, Institut Curie, Paris 75005, France; Factulty of Medicine, University of Paris Descartes, Paris 75005, France.
Olivier CussenotCeRePP, Tenon Hospital, Paris 75020, France; Sorbonne University, GRC n°5 Predictive Onco-Urology, AP-HP, Tenon Hospital, Paris 75020, France; University of Oxford, Nuffield Department of Surgical Sciences, Oxford, UK.
Géraldine Cancel-TassinCeRePP, Tenon Hospital, Paris 75020, France; Sorbonne University, GRC n°5 Predictive Onco-Urology, AP-HP, Tenon Hospital, Paris 75020, France.
Raphael MargueronInstitut Curie, PSL Research University, Sorbonne University, Inserm U934/ CNRS UMR3215, 26, rue d'Ulm, 75005 Paris, France.
Josselin NoirelLaboratoire GBCM (EA7528), CNAM, HESAM Université, Paris, France.
Jessica Zucman-RossiCentre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, 75006 Paris, France; Functional Genomics of Solid Tumors laboratory, Équipe labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, 75006 Paris, France; Hôpital Européen Georges Pompidou, APHP, 75015, Paris, France.
Manuel RodriguesInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France; Institut Curie, PSL Research University, Department of Medical Oncology, Paris 75005, France.
Marc-Henri SternInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe labellisée par la Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris 75005, France. Electronic address: marc-henri.stern@curie.fr.
Inserm · FRSorbonne Université · FRUniversité Paris Sciences et Lettres · FRCentre National de la Recherche Scientifique · FRConservatoire National des Arts et Métiers · FRDélégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TERT/CLPTM1L risk locus on chromosome 5p15.33 is a pleiotropic cancer risk locus in which multiple independent risk alleles have been identified, across well over ten cancer types. We previously conducted a genome-wide association study in uveal melanoma (UM), which uncovered a role for the TERT/CLPTM1L risk locus in this intraocular tumor and identified multiple highly correlated risk alleles. Aiming to unravel the biological mechanisms in UM of this locus, which contains a domain enriched in active chromatin marks and enhancer elements, we demonstrated the allele-specific enhancer activity of this risk region using reporter assays. In UM, we identified the functional variant rs452384, of which the C risk allele is associated with higher gene expression, increased CLPTM1L expression in UM tumors, and a longer telomere length in peripheral blood mononuclear cells. Electrophoretic mobility shift assays and quantitative mass spectrometry identified NKX2.4 as an rs452384-T-specific binding protein, whereas GATA4 preferentially interacted with rs452384-C. Knockdown of NKX2.4 but not GATA4 resulted in increased TERT and CLPTM1L expression. In summary, the UM risk conferred by the 5p locus is at least partly due to rs452384, for which NKX2.4 presents strong differential binding activity and regulates CLPTM1L and TERT expression. Altogether, our work unraveled some of the complex regulatory mechanisms at the 5p15.33 susceptibility region in UM, and this might also shed light on shared mechanisms with other tumor types affected by this susceptibility region.

Indexed as

Genome-Wide Association StudyUveal NeoplasmsAllelesHumansLeukocytes, MononuclearMelanomaUveal Melanomacancer geneticsfunctional genomicsTERT/CLPTM1Luveal melanoma

Identifiers

PMID36459980
PMCPMC9748249
OpenAlexW4311071005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.